Researchers from Dana-Farber Cancer Institute, the U.S. Food and Drug Administration (FDA) and the American Association for Cancer Research (AACR) are releasing recommendations designed to address the under-representation
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. REVLIMID® (lenalidomide) Consumer Medicine Information WARNING: Revlimid (lenalidomide) is structurally related to ‘thalidomide’, which is
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. KYPROLIS® Carfilzomib (kar FILZ oh mib) Consumer Medicine Information (CMI) What is in this leaflet
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was
Too many patients with cancers like multiple myeloma relapse after treatment. This grim reality motivated researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of
A drug has been made available on the NHS in England for adults with a type of blood cancer called multiple myeloma who cannot receive standard treatment. The
(HealthDay)—A safety statement was issued yesterday by the U.S. Food and Drug Administration regarding risks found to be associated with the investigational use of Venclexta (venetoclax) for treatment
THOUSAND OAKS, Calif., Oct. 1, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok
